Det var tilladt for patienterne at være enten fri for sygdomsmodificerende antireumatisk lægemiddel eller at forblive i deres allerede eksisterende reumatologiske terapi, forudsat at terapien havde været stabil i mindst 28 dage.
Patients were permitted to be either disease-modifying, anti-rheumatic drug-naïve or to remain on their pre-existing rheumatologic therapy provided that Me